Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study
Kyriakos P Papadopoulos, Taofeek K Owonikoko, Melissa L Johnson, Irene Brana, Marta Gil-Martin, Raymond P Perez, Victor Moreno, April K Salama, Emiliano Calvo, Nelson S Yee, Howard Safran, Antonio Gonzalez-Martin, Raid Aljumaily, Daruka Mahadevan, Kosalai K Mohan, Jingjin Li, Elizabeth Stankevich, Israel Lowy, Matthew G Fury, Jade Homsi
Abstract not available.
Disclosures: Study sponsored by Regeneron Pharmaceuticals Inc. and Sanofi.
Copyright 2018 SKIN
cutaneous squamous cell carcinoma; non-melanoma skin cancer; safety; efficacy; PD-1
Abstract - 440 Poster PDF - 345
- There are currently no refbacks.